Wells Fargo maintained a cautious Equal Weight stance while Goldman Sachs raised its target price to $42 for Arcus Biosciences.
1 report, 1 independent
Updated Aug 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Wells Fargo maintained a cautious Equal Weight stance while Goldman Sachs raised its target price to $42 for Arcus Biosciences.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Arcus Biosciences
biopharmaceutical company
Nothing else this week.
-
Wells Fargo
American multinational banking and financial services company
-
Goldman Sachs
American investment bank
Related events
- Wells Fargo raised its price target for The Home Depot, Inc. on August 16, 2026.
- Investment activity in Wells Fargo involving Capital Research Global Investors and Norges Bank, with a 4.9% stake increase reported in the 4th quarter.
- Analyst cut price target due to pricing pressure for Carnival Corporation, involving Wells Fargo.
- Cantor Fitzgerald and Wells Fargo raised price targets for Regeneron Pharmaceuticals stock.
- Wells Fargo raised its price objective for Urban Outfitters stock, and Jefferies Financial Group lifted its price target for the company on August 1, 2026.